Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of “Hold” from Brokerages

Immuneering Co. (NASDAQ:IMRX) has earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.80.

Several equities research analysts have recently weighed in on IMRX shares. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Chardan Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Immuneering in a report on Tuesday.

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. purchased a new stake in shares of Immuneering during the 3rd quarter worth about $25,000. Corsair Capital Management L.P. acquired a new position in Immuneering in the third quarter worth approximately $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering in the second quarter valued at approximately $44,000. XTX Topco Ltd grew its position in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after acquiring an additional 9,274 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Immuneering during the 2nd quarter worth $67,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Stock Performance

Shares of NASDAQ:IMRX opened at $2.00 on Thursday. The stock has a market capitalization of $62.10 million, a price-to-earnings ratio of -1.02 and a beta of -0.34. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The company has a 50 day moving average price of $2.04 and a 200 day moving average price of $1.77.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.